Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T63551
(Former ID: TTDNC00629)
|
|||||
| Target Name |
Integrin (ITG)
|
|||||
| Synonyms |
Integrin protein
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Retinopathy [ICD-11: 9B71] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | THR-687 | Drug Info | Phase 1 | Diabetic macular edema | [2] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Antagonist | [+] 1 Antagonist drugs | + | ||||
| 1 | THR-687 | Drug Info | [3] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Safety, tolerability, and pharmacokinetics of the novel alphav-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. Invest New Drugs. 2014 Apr;32(2):347-54. | |||||
| REF 2 | ClinicalTrials.gov (NCT03666923) A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME). U.S. National Institutes of Health. | |||||
| REF 3 | The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders. Exp Eye Res. 2019 Mar;180:43-52. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.